The quantitative ADAM questionnaire: A new tool in quantifying the severity of hypogonadism

International Journal of Impotence Research

Volumn 22, Issue 1, 2010, Pages 20-24

  Mohamed, O ^a   Freundlich, R E ^a   Dakik, H K ^a   Grober, E D ^b   Najari, B ^c   Lipshultz, L I ^a   Khera, M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Androgen deficiency; Hypogonadism; Testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ANDROGEN DEFICIENCY IN THE AGING MALE QUESTIONNAIRE; ARTICLE; BLOOD SAMPLING; DISEASE SEVERITY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

AGED; ANDROGENS; HEALTH STATUS; HUMANS; HYPOGONADISM; LIBIDO; MALE; MIDDLE AGED; PENILE ERECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUESTIONNAIRES; SEXUAL BEHAVIOR; SEXUALITY; TESTOSTERONE;

EID: 75149172689     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2009.35     Document Type: Article

References (24)

1. Morales A, Tenover JL. Androgen deficiency in the aging male: when, who, and how to investigate and treat. Urol Clin North Am 2002; 29: 975-982.
2. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-2745.
3. Kiratli BJ, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132.
4. Stoch SA, Parker RA, Chen L, Bubley G, Ko YJ, Vincelette A et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787-2791.
5. Stepan JJ, Lachman M, Zverina J, Zverina J, Pacovsky V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 1989; 69: 523-527.
6. Riggs BL, Wahner HW, Seeman E, Offord KP, Dunn WL, Mazess RB et al. Changes in bone mineral density of the proximal femur and spine with aging. J Clin Invest 1982; 70: 716-723.
7. Murray MP, Gardner GM, Mollinger LA, Sepic SB. Strength of isometric and isokinetic contractions: knee muscles of men aged 20-86. Phys Ther 1980; 60: 412-419.
8. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 407-413. (Pubitemid 27068601)
9. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M et al. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83: 1886-1892.
10. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002; 87: 5001-5007.
11. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653-663.
12. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358-4365.
13. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57: 557-562.
14. Davidson JM, Camargo CA, Smith ER. Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 1979; 48: 955-958.
15. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men. J Clin Endocrinol Metab 1983; 57: 71-77.
16. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242.
17. Martínez-Jabaloyas JM, Queipo-Zaragozá A, Rodríguez- Navarro R, Quiepo-Zaragoza JA, Gil-Salom M, Chuan-Nuez P. Relationship between the Saint Louis University ADAM Questionnaire and sexual hormonal levels in a male outpatient population over 50 years of age. Eur Urol 2007; 52: 1760-1767.
18. Vroege JA. The sexual health inventory for men (IIEF-5). Int J Impot Res 1999; 11: 177.
19. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905.
20. Likert R. A technique for the measurement of attitudes. Arch Psychol 1932; 140: 1-55.
21. Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X et al. The Aging Males' Symptoms Scale: update and compilation of international versions. Health Qual Life Outcomes 2003; 1: 15.
22. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80-87. (Pubitemid 38748514)
23. O'Leary MP. Development of an index to evaluate symptoms in men with androgen deficiency. Rev Urol 2003; 5(Suppl 1): S11-S15.
24. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab 1983; 56: 1278-1281.